Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2005 / Cilt: 15 - Sayı: 3

Daunorubicin induced blue-gray hyperpigmentation: A case report

Daunorubisin'e bağlı blue-gray hiperpigmentasyon: Bir olgu sunumu

Pages
149–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We report here a hyperpigmentation case with acute myelomonocytic leukemia who is still on the treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Daunorubicin is used widely in the treatment of acute myeloblastic leukemia (AML).
📊
Key Findings & Data:Daunorubicin has some toxicity which limit the usage of drug.
💡
Conclusion & Impact:We report here a hyperpigmentation case with acute myelomonocytic leukemia who is still on the treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lösemi · miyeloid · İlaç aşırı duyarlılığı

Abstract

Daunorubicin is used widely in the treatment of acute myeloblastic leukemia (AML). Daunorubicin has some toxicity which limit the usage of drug. Blue-gray pigmentation is an uncommon side effect of daunorubicin. It is one of the side effect which might disturb patient for a long time cosmetically. We report here a hyperpigmentation case with acute myelomonocytic leukemia who is still on the treatment.

Özet

Daunorubisin akut miyeloblastik lösemilerin (AML) tedavisinde yaygın kullanılan antineoplastik bir ilaçtır. AML remisyon-indüksiyon tedavisinde oldukça etkin olan bu ilacın kullanımını kısıtlayan yan etkilerinin yanında, nadir görülen yan etkileri de vardır. Bunlardan birisi de kozmetik olarak hastayı rahatsız eden, uzun süre devam edebilen Blue-gray pigmentasyondur. Bu nedenle, AML-M4 tanısı ile Daunorubisin başladığımız ve blue-gray hiperpigmentasyon gelişen, halen takip altında olan bir olguyu sunmayı uygun gördük.

🔖

Cite This Article

AYYILDIZ, O., ŞİT, D., SÖKER, M., KADİROĞLU, A. K., YEŞİLBAĞDAN, A. H. (2005). Daunorubicin induced blue-gray hyperpigmentation: A case report. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 15 - Sayı: 3, 149–152. https://ajindex.com/articles/323102

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Capranico G, Butelli E, Zunnino F. Change of sequence specificity of daunorubicine-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety. Cancer Res 55:312, 1995. 2. Lichtman MA, Liesveld JL: Acute Myelogenous Leukemia. Williams Hematology,(Eds) Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, McGraw-Hill, St. Louis, 2001:1048- 1083. 3. Mouton RW, Jordaan HF, Schneider JW. A new type of minocycline-induced cutaneous hyperpigmentation. Clin Exp Dermatol 29(1):8-14, 2004. 4. Kroumpouzos G, Travers R, Allan A. Generalized hyperpigmentation with daunoru-bicin chemotherapy. J Am Acad Dermatol 46(2 Suppl Case Reports):S1-3, 2002. 5. Sanchez AR, Rogers RS, Sheridan PJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol 43(10):709-15, 2004. 6. Kounis NG, Frangides C, Papadaki PJ, Zavras GM, Goudevenos J. Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation. Clin Cardiol 19(7):592-594, 1996. 7. Angel TA, Stalkup JR, Hsu S. Photodistributed blue-gray pigmentation of the skin associated with long-term imipramine use. Int J Dermatol 41(6):327-9, 2002. 8. Kleinegger CL, Hammond HL, Finkelstein MW. Oral mucosal hyperpigmentation secondary to antimalarial drug therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90(2):189-94, 2000.